
A recent study assessed the impact of COVID-19-related changes in treatment patterns on visual acuity in patients with neovascular age-related macular degeneration (nAMD). The results revealed that during the pandemic in 2020, the mean number of anti-VEGF injections significantly decreased compared to pre-pandemic and post-pandemic periods. The lower injection ratio per patient/month during COVID-19 persisted, with a noticeable decline in March-April 2020. Despite these changes in treatment, the study found that they did not significantly impact best-corrected visual acuity (BCVA) outcomes. These findings provide valuable insights into the management of nAMD during health crises like COVID-19.
Like
Save
Share